Last reviewed · How we verify
NCT06288529
EFFECT SGLT2 INHIBITORS ON CONTRAST MEDIUM INDUCED ACUTE KIDNEY INJURY
trial in Chronic Kidney Diseases in 975 participants. Completed in 31 January 2024.
31 December 2023
Quick facts
| Lead sponsor | University of Health Sciences Balikesir Hospital Eduation and Research |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 975 |
| Start date | 15 July 2023 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 January 2024 |
| Sites | 1 location across Turkey (Türkiye) |
Conditions studied
- Chronic Kidney Diseases — all drugs for Chronic Kidney Diseases →
- Type2diabetes — all drugs for Type2diabetes →
Sponsor
University of Health Sciences Balikesir Hospital Eduation and Research
Who can join
Adults 18 to 75, any sex, with Chronic Kidney Diseases or Type2diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Chronic kidney disease and type 2 diabetes mellitus patients are with in high-risk patients in coronary arterial diseases and increasing number of coronary angiography and coronary interventional procedures have been performed in these population. As well as the risk factors have been identified by many studies preventive measures are lacking. In our study we found that SGLT2 inhibitors are beneficial in terms of reducing contrast media induced acute kidney injury in both diabetic and CKD patients.This is one of the leading studies in the literature pointing that SGLT2 inhibitors may have a potentially beneficial role in reducing or preventing the development of PC-AKI.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06288529
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Kidney Diseases
Currently open trials in the same condition.
- NCT06593392 — Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus · Phase 2 · recruiting
- NCT07358572 — Eye-Brain-Kidney in CKD · recruiting
- NCT06463483 — Automated Insulin Delivery in Adults With Advanced Kidney Disease · NA · recruiting
- NCT06927024 — Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD) · NA · recruiting
- NCT07115953 — Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension · NA · recruiting
Other University of Health Sciences Balikesir Hospital Eduation and Research trials
Trials by the same sponsor.
- NCT07376798 — Effect of Patient Position on Bupivacaine Dose Requirement and Hemodynamic Stability in Spinal Anesthesia · NA · not yet recruiting
- NCT07388160 — Neuroinflammatory Biomarkers After General Anesthesia: A Comparison Study · not yet recruiting
- NCT07369544 — The Effect of Preoperative Hugging With Family Members on Preoperative Anxiety Levels and Postoperative Pain · NA · active not recruiting
- NCT07240584 — Exercise Prehabilitation of Breast Cancer · NA · completed
- NCT07301580 — Prehabilitation of Breast Cancer-Related Lymphedema · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06288529 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Health Sciences Balikesir Hospital Eduation and Research
- Last refreshed: 1 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06288529.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing